Biological barriers to therapy with antisense and siRNA oligonucleotides.
about
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeuticsTherapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosisDesign and application of multifunctional DNA nanocarriers for therapeutic deliverysiRNA delivery to the lung: what's new?Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor.Multicellular tumor spheroids as a model for assessing delivery of oligonucleotides in three dimensionsPoly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium.Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.Efficient and targeted delivery of siRNA in vivo.Significance and applications of nanoparticles in siRNA delivery for cancer therapy.Anti-tumor activity of splice-switching oligonucleotides.Layer-by-layer assembled antisense DNA microsponge particles for efficient delivery of cancer therapeutics.Tumor cell-targeted delivery of nanoconjugated oligonucleotides in composite spheroidsAntisense therapy in neurologyRNA interference for improving the outcome of islet transplantation.Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through.Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexesMolecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.DNA nanostructures: a shift from assembly to applications.High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides.Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.In vivo sustained release of siRNA from solid lipid nanoparticles.Delivery of siRNA to the mouse lung via a functionalized lipopolyamine.Nanotechnology and the treatment of HIV infection.Small-molecule approaches toward the targeting of oncogenic miRNAs: roadmap for the discovery of RNA modulators.A comparative study of three ternary complexes prepared in different mixing orders of siRNA/redox-responsive hyperbranched poly (amido amine)/hyaluronic acidRetro-1 Analogues Differentially Affect Oligonucleotide Delivery and Toxin Trafficking.A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML.The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides.Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotidesBiodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model.Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.Oligonucleotide-based tools for studying zebrafish development.Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function.The biological and therapeutic relevance of mRNA translation in cancer.Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.Integrin targeted delivery of gene therapeuticsNanocarriers: a tool to overcome biological barriers in siRNA delivery.Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides.
P2860
Q24616751-5E15A2A1-C12B-4644-808F-F5D3A000477DQ26782089-B6E53D08-D031-4622-9338-62624DB5E78DQ27007011-E201E87D-D607-469B-BFE2-800A40DB2BB1Q27022043-C8985C92-13B6-4777-B378-68AD63CD2266Q30365844-209B1ED0-B7A8-4400-AC99-05C1E3E4A9DEQ30434397-31013A5B-9A8B-42A9-9821-9BCFE3B865FBQ33637214-94510F36-E84C-46FE-855D-9566F4B5DA64Q33732559-E8203024-67C4-499B-A424-29EFD061B5DDQ33935474-D2A8C621-816B-4AF9-BC39-2E6103631D1FQ34149828-8E61B61B-5919-452E-ADCB-5EADAB8139C4Q34297263-A9B23C5C-0001-469B-937E-50A8B909ED91Q34401490-3D0B31EB-C833-40D0-B7A8-143C7E136687Q34419904-46BFCDA9-0372-4FD1-B20C-9ABF19821641Q34606502-A83B3F77-B0EE-4335-8FAD-ADED2CDAADB7Q34608717-33776C9E-F320-49BE-AD25-56B395D15AD9Q34729434-998F5798-91E7-42E1-9922-9E8ED4F6FA6BQ35072755-2571308B-A852-4C0B-BB47-8B57AFF15CA2Q35097999-AC42F3F1-201F-4C32-8048-96D7E1779575Q35113870-EA1035F8-7E1D-42C5-9E24-004A04050045Q35115883-5416F687-ECF5-4487-BA0D-6A121ED28BAFQ35131115-168C6855-400F-43B9-B876-25FC738A6D8AQ35237068-62E8D6DC-1102-4100-8250-EDD61E46BBC1Q35635763-2E9A8C26-2FA9-4AE7-BE81-A07EA4BC674FQ35665154-ECAF68A3-E55D-42B0-AA37-123007DAA03EQ35943647-4818EB7B-0413-44D1-B8A9-3CD6A1CDCC17Q36009522-769589E3-BEAA-438B-B1F1-A778BE889B69Q36148620-0EC98C2C-A1FB-4C77-836C-F0DC8A9D61B0Q36173801-17041753-B7BF-45CA-A642-2873D8692CCCQ36726848-49837DC0-E875-4FDC-8516-8000D037C4C4Q36740806-ADDA9ECD-92F3-485F-841A-F2719467B333Q37015817-8BBBC566-829D-4F05-9EF6-2EE4022E7789Q37234573-4D477C5B-D6D1-4169-96A4-AFED22510437Q37656119-68F9CDD8-00F0-4117-94DE-C207213368EEQ37730851-D43021BB-D646-4285-9A0E-0FDB52EBA36CQ37734660-DC9EC1C2-CB2B-49A9-A4ED-CF708BEE20CEQ37848652-F10BCE13-9D17-4732-BDCA-293C44C14B0FQ37850458-15B0388E-B52D-4913-A2B7-C96125C71EBCQ37872613-C1562ECB-902A-4215-8174-52A6FEA80C11Q37891091-7752091D-4DFD-413E-8868-3FE93C59D1D2Q37944929-65B5CE85-8733-4B7D-8A06-C64F50A89A92
P2860
Biological barriers to therapy with antisense and siRNA oligonucleotides.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biological barriers to therapy with antisense and siRNA oligonucleotides.
@en
Biological barriers to therapy with antisense and siRNA oligonucleotides.
@nl
type
label
Biological barriers to therapy with antisense and siRNA oligonucleotides.
@en
Biological barriers to therapy with antisense and siRNA oligonucleotides.
@nl
prefLabel
Biological barriers to therapy with antisense and siRNA oligonucleotides.
@en
Biological barriers to therapy with antisense and siRNA oligonucleotides.
@nl
P2093
P2860
P356
P1476
Biological barriers to therapy with antisense and siRNA oligonucleotides.
@en
P2093
P2860
P304
P356
10.1021/MP900093R
P407
P577
2009-05-01T00:00:00Z